Sarepta Therapeutics (Sarepta Therapeutics) GF Value Rank : 9 (As of Apr. 27, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics GF Value Rank?

Sarepta Therapeutics has the GF Value Rank of 9.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Sarepta Therapeutics's GF Value Rank

For the Biotechnology subindustry, Sarepta Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's GF Value Rank falls into.

Sarepta Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Executives

Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme	officer: Senior Vice President, CFO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901